Monofer Side Effects
Monofer (ferric derisomaltose) has a favorable safety profile with the most common side effects being rash (1%) and nausea (1.2%), while serious hypersensitivity reactions occur in only 0.3% of patients, and true anaphylaxis is exceedingly rare at less than 1 in 200,000 administrations 1.
Common Side Effects
The FDA-approved labeling identifies the following adverse reactions occurring in ≥1% of patients 1:
- Nausea: 1.2% of patients
- Rash: 1.0% of patients
These rates are based on pooled data from 2,008 patients receiving a single 1000 mg intravenous dose across two major clinical trials.
Serious but Rare: Hypersensitivity Reactions
CARPA vs. True Anaphylaxis
The most important distinction for clinicians is understanding that most infusion reactions are not true allergic reactions 2:
CARPA (Complement Activation-Related Pseudo-Allergy): The most common type of reaction, characterized by flushing, myalgias, arthralgias, back pain, and chest pressure. This occurs due to labile free iron release and does not involve IgE-mediated mechanisms. It typically occurs at the beginning of infusion, is self-limited, and usually resolves without treatment.
True IgE-mediated anaphylaxis: Exceedingly rare (<1:200,000 administrations) 2. Characterized by systemic hypotension, wheezing, peri-orbital edema, respiratory stridor, or gastrointestinal pain.
In clinical trials, adjudicated serious or severe hypersensitivity reactions occurred in only 0.3% (6/2008) of Monofer-treated patients 1.
Real-World Safety Data
A large retrospective study of 7,354 patients treated with ferric derisomaltose (Monofer) in UK clinical practice demonstrated 3:
- Any adverse reactions: 1.7%
- Hypersensitivity reactions: 0.4%
- Anaphylaxis: <0.1%
An Asian population study showed a slightly higher rate of hypersensitivity reactions at 7.29%, with 68% occurring within the first hour 4. Most resolved with antihistamine administration alone.
Other Notable Side Effects
Hypophosphatemia
Serum phosphate levels <2.0 mg/dL were reported in 3.5% of patients in clinical trials 1. However, Monofer (iron isomaltoside) does not appear to be associated with clinically significant hypophosphatemia compared to other IV iron formulations 5, which is an important advantage over ferric carboxymaltose.
Post-Marketing Reported Effects
The following have been reported voluntarily but frequency cannot be reliably determined 1:
- Musculoskeletal: Back pain, muscle spasms, arthralgia, myalgia
- Neurological: Dizziness, headache, paresthesia, dysgeusia, seizure, loss of consciousness, syncope
- Respiratory: Dyspnea, cough, bronchospasm
- Cardiovascular: Hypertension, hypotension, flushing, phlebitis
- Dermatologic: Erythema, urticaria, skin discoloration, pruritus, angioedema
- Laboratory: Elevated hepatic enzymes
- Extravasation: Can cause skin irritation and potentially long-lasting brown discoloration at injection site
Infection Risk Consideration
A critical caveat: A 2021 meta-analysis found that intravenous iron overall is associated with a 16% increased risk of infection (RR 1.16; 95% CI 1.03-1.29) 6. This risk must be balanced against the benefits of correcting iron deficiency, including improved hemoglobin levels and reduced transfusion requirements. The mechanism relates to increased circulating non-transferrin-bound iron potentially promoting pathogen growth.
Clinical Management Recommendations
Based on expert consensus guidelines 2:
Pre-infusion assessment should identify high-risk patients:
- History of severe asthma or eczema
- Mastocytosis
- Multiple drug allergies
- Prior reaction to IV iron
During infusion:
- Start at a slow rate (slower rates associated with fewer reactions)
- Close observation during first 10 minutes (immediate reactions occur within first minute)
- Monitor vital signs
If reaction occurs:
- Stop infusion immediately
- Assess symptoms to differentiate CARPA from anaphylaxis
- CARPA typically resolves without treatment or with antihistamines
- True anaphylaxis requires epinephrine and emergency management
Post-infusion:
- Educate patients about delayed reactions (flu-like symptoms, arthralgias, myalgias, fevers) manageable with NSAIDs
- Monitor phosphate levels if clinically indicated
Key Advantages of Monofer
The structure of iron isomaltoside allows for tightly bound iron in a matrix structure with 5:
- Low immunogenic potential
- Low potential to release labile iron
- High-dose administration capability (up to 20 mg/kg body weight)
- Single-dose infusion possible (1000 mg over 20 minutes)
This favorable profile makes Monofer one of the safer IV iron formulations available, with the 2024 expert consensus identifying it as an optimal formulation for total dose infusion 2.